Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure. By attending this educational activity, you will learn about the impact of HI on the pharmacokinetics (PK) and safety of cobimetinib.

The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.

Presented by: Luke Delzer, PharmD, Clinical Pharmacist, Kaiser Permanente

Presented by: Alexander Vinks, PharmD, PhD, FCP, Professor and Div Director, Cincinnati Children’s Hosp Medical Ctr, Clinical Pharmacology and Henry Akinbi, MD, Director of Education, Cincinnati Children’s Hosp Medical Ctr, Perinatal Inst

Presented by: William D. Figg, PharmD, Senior Investigator, Natl Cancer Inst of the Natl Inst of Health, Molecular and Clinical Pharmacology Program. Learners that complete this course will be able to provide a comprehensive overview of clinically-relevant biomarkers and molecular profiling platforms in precision oncology medicine to optimize cancer treatment outcomes.